Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-290.8M
Cash
291.8M
Avg Qtr Burn
N/A
Short % of Float
27.86K%
Insider Ownership
6.42%
Institutional Own.
99.61%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELVN-002 monotherapy Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 1 Data readout | |
ELVN-002 w/ trastuzumab +/- chemotherapeutic agents Details Cancer, Metastatic breast cancer, Metastatic colorectal cancer | Phase 1a Data readout | |
ELVN-001 Details Chronic myelomonocytic leukemia, Blood cancer, Cancer | Phase 1a Data readout |